Organigram Global (OGI) Cash from Investing Activities (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash from Investing Activities of -$4.2 million for Q1 2026, up 41.53% year-on-year from -$3.0 million in Q1 2025, and down 34.72% on a QoQ basis from -$3.1 million in Q4 2025.
Organigram Global (OGI) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash from Investing Activities for 7 consecutive years, with -$4.2 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 41.53% year-over-year to -$4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.6 million (up 65.75% YoY) and the FY2025 annual result came in at -$58.9 million, down 160.87% from the prior year.
- Cash from Investing Activities retreated to -$4.2 million in Q1 2026 per OGI's latest filing, from -$3.1 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for OGI reached as high as -$3.1 million in Q4 2025 and fell as low as -$44.1 million in Q4 2024.
- A 3-year average of -$14.6 million and a median of -$5.7 million in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2025 — Cash from Investing Activities soared 92.93% — and 2026, when it soared 41.53%.
- Year by year, Cash from Investing Activities stood at -$44.1 million in 2024, then surged by 92.93% to -$3.1 million in 2025, then tumbled by 34.72% to -$4.2 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4.2 million, -$3.1 million, and -$7.2 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.88 Bn | 32.14 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.64 Bn | 30.70 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.04 Bn | 20.88 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.37 Bn | 18.57 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.45 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Organigram Global | 120.15 Mn | 153.23 Mn | 28.97 Mn | -4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.20 Mn |
| Mar 31, 2026 | -4.20 Mn |
| Dec 31, 2025 | -3.12 Mn |
| Dec 31, 2025 | -3.12 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Dec 31, 2024 | -44.06 Mn |
| Dec 31, 2024 | -44.06 Mn |
| May 31, 2021 | -153.91 Mn |
| May 31, 2021 | -153.91 Mn |
| Feb 28, 2021 | 34.18 Mn |
| Feb 28, 2021 | 34.18 Mn |
| Nov 30, 2020 | 15.81 Mn |
| Nov 30, 2020 | 15.81 Mn |
| Aug 31, 2020 | -177.81 Mn |
| Aug 31, 2020 | -177.81 Mn |
| May 31, 2020 | 32.68 Bn |
| May 31, 2020 | 32.68 Bn |
| Feb 29, 2020 | 68,052.00 |
| Feb 29, 2020 | 68,052.00 |